April 29 (Reuters) - Gen-Probe Inc (GPRO.O) reported better-than-expected first-quarter results, helped by a nearly 30 percent rise in sales of its clinical diagnostics products, and raised the lower end of its full-year outlook.
April 29 (Reuters) - Gen-Probe Inc (GPRO.O) reported better-than-expected first-quarter results, helped by a nearly 30 percent rise in sales of its clinical diagnostics products, and raised the lower end of its full-year outlook.
